MY168413A - Amino-substituted imidazopyridazines - Google Patents
Amino-substituted imidazopyridazinesInfo
- Publication number
- MY168413A MY168413A MYPI2014700492A MYPI2014700492A MY168413A MY 168413 A MY168413 A MY 168413A MY PI2014700492 A MYPI2014700492 A MY PI2014700492A MY PI2014700492 A MYPI2014700492 A MY PI2014700492A MY 168413 A MY168413 A MY 168413A
- Authority
- MY
- Malaysia
- Prior art keywords
- compounds
- amino
- substituted imidazopyridazines
- substituted
- imidazopyridazines
- Prior art date
Links
- -1 Amino-substituted imidazopyridazines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11180129 | 2011-09-06 | ||
| EP11182440 | 2011-09-23 | ||
| EP12179902 | 2012-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168413A true MY168413A (en) | 2018-11-09 |
Family
ID=47831558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014700492A MY168413A (en) | 2011-09-06 | 2012-09-05 | Amino-substituted imidazopyridazines |
Country Status (36)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012163942A1 (en) | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| US9320737B2 (en) * | 2011-09-23 | 2016-04-26 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CA2858685A1 (en) | 2011-12-12 | 2013-06-20 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| WO2013144189A1 (en) * | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| JP6173430B2 (ja) | 2012-04-04 | 2017-08-02 | バイエル・ファルマ・アクティエンゲゼルシャフト | アミノ置換イミダゾピリダジン |
| EP2920176B1 (en) | 2012-11-19 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines as mknk1 kinase inhibitors |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| JP2016506943A (ja) | 2013-01-30 | 2016-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類 |
| CN105143227A (zh) * | 2013-02-20 | 2015-12-09 | 拜耳医药股份公司 | 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物 |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| CA2936024A1 (en) | 2014-01-09 | 2015-07-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| CA2971536A1 (en) * | 2014-12-23 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines |
| JP6681919B2 (ja) | 2015-04-20 | 2020-04-15 | イーフェクター セラピューティクス， インコーポレイテッド | がんおよび感染症を処置する際に使用するための免疫チェックポイントモジュレーターの阻害剤 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4408047A (en) | 1980-03-28 | 1983-10-04 | Merck & Co., Inc. | Imidazodiazines |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| FR2619818B1 (fr) | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO2003018020A1 (fr) | 2001-08-23 | 2003-03-06 | Takeda Chemical Industries, Ltd. | Inhibiteurs de jnk |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| WO2007033080A2 (en) | 2005-09-12 | 2007-03-22 | Emory University | Alzheimer's disease imaging agents |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| CN101472912A (zh) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| CA2663091A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| MX2009004715A (es) | 2006-10-30 | 2009-05-20 | Novartis Ag | Compuestos heterociclicos como agentes antiinflamatorios. |
| AU2007316417B2 (en) | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| WO2009086130A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| EP2710004A1 (en) * | 2011-05-17 | 2014-03-26 | Bayer Intellectual Property GmbH | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| WO2012163942A1 (en) | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| ES2610366T3 (es) | 2011-06-22 | 2017-04-27 | Bayer Intellectual Property Gmbh | Heterociclil-aminoimidazopiridazinas |
| AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| US9320737B2 (en) | 2011-09-23 | 2016-04-26 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CA2858685A1 (en) | 2011-12-12 | 2013-06-20 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| WO2013144189A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines |
| JP6173430B2 (ja) | 2012-04-04 | 2017-08-02 | バイエル・ファルマ・アクティエンゲゼルシャフト | アミノ置換イミダゾピリダジン |
| EP2920176B1 (en) | 2012-11-19 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines as mknk1 kinase inhibitors |
| JP2016506943A (ja) | 2013-01-30 | 2016-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類 |
| CN105143227A (zh) | 2013-02-20 | 2015-12-09 | 拜耳医药股份公司 | 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物 |
| CA2936024A1 (en) | 2014-01-09 | 2015-07-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders |
-
2012
- 2012-05-09 UA UAA201403426A patent/UA117092C2/uk unknown
- 2012-09-05 HR HRP20171248TT patent/HRP20171248T1/hr unknown
- 2012-09-05 PH PH1/2014/500501A patent/PH12014500501A1/en unknown
- 2012-09-05 US US14/342,977 patent/US9499547B2/en not_active Expired - Fee Related
- 2012-09-05 LT LTEP12761564.9T patent/LT2758401T/lt unknown
- 2012-09-05 CA CA2847514A patent/CA2847514A1/en not_active Abandoned
- 2012-09-05 MY MYPI2014700492A patent/MY168413A/en unknown
- 2012-09-05 DK DK12761564.9T patent/DK2758401T3/en active
- 2012-09-05 JP JP2014528955A patent/JP6174583B2/ja not_active Expired - Fee Related
- 2012-09-05 ES ES12761564.9T patent/ES2638319T3/es active Active
- 2012-09-05 AU AU2012306422A patent/AU2012306422B2/en not_active Ceased
- 2012-09-05 WO PCT/EP2012/067264 patent/WO2013034570A1/en active Application Filing
- 2012-09-05 SI SI201231035T patent/SI2758401T1/sl unknown
- 2012-09-05 AP AP2014007496A patent/AP2014007496A0/xx unknown
- 2012-09-05 PE PE2014000307A patent/PE20141593A1/es not_active Application Discontinuation
- 2012-09-05 BR BR112014004687A patent/BR112014004687A2/pt not_active IP Right Cessation
- 2012-09-05 MX MX2014002697A patent/MX348064B/es active IP Right Grant
- 2012-09-05 KR KR1020147008395A patent/KR20140059268A/ko not_active Ceased
- 2012-09-05 EP EP12761564.9A patent/EP2758401B1/en active Active
- 2012-09-05 CN CN201280047525.XA patent/CN103958515B/zh not_active Expired - Fee Related
- 2012-09-05 PT PT127615649T patent/PT2758401T/pt unknown
- 2012-09-05 SG SG11201400219PA patent/SG11201400219PA/en unknown
- 2012-09-05 RS RS20170812A patent/RS56179B1/sr unknown
- 2012-09-05 PL PL12761564T patent/PL2758401T3/pl unknown
- 2012-09-05 EA EA201400311A patent/EA025688B1/ru not_active IP Right Cessation
- 2012-09-05 ME MEP-2017-191A patent/ME02951B/me unknown
-
2014
- 2014-03-05 MA MA36793A patent/MA35422B1/fr unknown
- 2014-03-06 DO DO2014000051A patent/DOP2014000051A/es unknown
- 2014-03-06 EC ECSP14013231 patent/ECSP14013231A/es unknown
- 2014-03-06 CL CL2014000543A patent/CL2014000543A1/es unknown
- 2014-03-06 CO CO14048372A patent/CO6900146A2/es unknown
- 2014-03-06 CR CR20140113A patent/CR20140113A/es unknown
- 2014-03-06 IL IL231351A patent/IL231351A/en not_active IP Right Cessation
- 2014-03-06 GT GT201400043A patent/GT201400043A/es unknown
- 2014-04-04 ZA ZA2014/02498A patent/ZA201402498B/en unknown
-
2017
- 2017-08-23 CY CY20171100892T patent/CY1119433T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500501A1 (en) | Amino-substituted imidazopyridazines | |
| MY185139A (en) | Substituted imidazopyridazines | |
| PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| TN2015000371A1 (en) | Substituted imidazopyridazines | |
| PH12016501581A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| PH12016501807A1 (en) | Novel compounds | |
| PH12020500134A1 (en) | Dihydrooxadiazinones | |
| PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
| PH12017501133A1 (en) | Pyrazolopyridinamines | |
| MX2014007057A (es) | Triazolopiridinas sustituidas. | |
| PH12016500931A1 (en) | Thienopyrimidines as mknk1 and mknk2 inhibitors | |
| WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
| PH12016501932A1 (en) | Amido-substituted azole compounds | |
| WO2010051933A3 (en) | Substituted sulphonamido phenoxybenzamides | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| TN2014000091A1 (en) | Amino-substituted imidazopyridazines | |
| TN2013000099A1 (en) | Substituted imidazopyridazines | |
| MA39762A (fr) | Nouveaux composés | |
| TN2013000204A1 (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |